Effective January 1, 2021, Amgen discontinued voluntary “340B-like” discounts on their orphan drugs. This applies to Critical Access Hospitals, Sole Community Hospitals, Rural Referral Centers and Free-Standing Cancer Centers.
These are the actions we have taken:
- Reinstated Amgen NDCs as orphan drugs on the Macro Helix Orphan Drug List
- Removed Amgen orphan NDCs from the PID’s Orphan Exception List
- Placed those NDCs on the ‘Do Not Order List’ for impacted PIDs
- Created an impact report (RID 450) for Macro Helix Hospital Administrator-level users
Contact your wholesaler for any questions about pricing.
340B Price Restoration: Bulk Exclusions